Advanced Micro Devices (AMD) reachead $170.97 at the closing of the latest trading day, reflecting a +0.04% change compared to its last close.
Advanced Micro Devices (AMD) will hold its "Advancing AI" event this week, with analysts expecting new product announcements that could drive the stock higher and lift sales.
AMD achieved its target price of $160 and now focuses on aggressive AI hardware expansion to challenge Nvidia's dominance. The Instinct MI300X GPUs, with up to 16,384 GPUs per supercluster, position AMD as a top contender for AI infrastructure. Q2 2024 saw 115% YoY revenue growth in AMD's data center segment, accounting for nearly half of the company's total revenue.
AMD rides on upbeat industry sales data, strong portfolio, ZT and Silo acquisitions, and robust data center demand amid stiff competition from NVIDIA.
Artificial-intelligence-chip stocks had a rough third quarter, but the rest of the year looks brighter, Melius Research says.
Last year's Advancing AI event spurred a major rally in AMD shares. Here's what investors are looking for at this year's.
Most companies are gearing up to announce their Q3 2024 earnings reports, which are likely to influence investor interest in their respective stocks, with an artificial intelligence (AI) tool offering insights on entities likely to stand out.
The AMD (NASDAQ: AMD) stock price has crawled back in the past few weeks, rising from the August low of $121.80 to the current $170. It has jumped by over 208% from its lowest point in 2020.
Advanced Micro Devices (AMD) is gearing up to showcase new tech at its 2024 Advancing AI event on Thursday, which Bank of America analysts said could be a "catch-up catalyst" for the chipmaker.
Advanced Micro Devices, Inc. (AMD, Financial)'s stock has surged by 22.61% year-to-date, despite facing short-term headwinds on its first semester's report. This uptrend is believed to continue.
Excitement is building for AMD's upcoming AI event.
4D Molecular Therapeutics' lead candidate, 4D-150, aims to provide a one-time gene therapy for Wet-AMD, showing promising but mixed Phase 2 data. Despite setbacks, 4D-150's potential for less frequent dosing and robust safety profile make it an intriguing investment, especially given 4D's strong cash position. The competitive landscape is fierce, with rivals like AbbVie and Adverum, but 4D-150 could still achieve significant market share if approved.